Infection News

Although progress has been made in eliminating mother-to-child transmission of hepatitis B by 2030, 26% of countries have not introduced a birth dose into routine hepatitis B vaccination, noted data in Morbidity and Mortality Weekly Report.

Receiving an mRNA or inactivated COVID-19 vaccine did not increase the risk for acute liver injury, according to a study published in Journal of Hepatology.

Patients with cirrhosis who have hepatitis B virus infection and a history of heavy alcohol use are at higher risk for hepatocellular carcinoma and mortality, according to a study published in JAMA Network Open.

In a Healio video exclusive, Chari Cohen, DrPH, MPH, president of the Hepatitis B Foundation, and Jeff Baxter, president and CEO of VBI Vaccines, shared insights on the latest efforts in HBV treatment and prevention.

Individuals born in the United States made up nearly two-thirds of all hepatitis B-listed deaths, with death rates exceeding the national average in 13 states, according to research published in JAMA Network Open.

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress.

An environmental hygiene program meant to improve cleaning thoroughness led to a sustained 50% decrease in health care-onset Clostridioides difficile infection in eight hospitals, a study found.

SAN DIEGO — In a Healio video exclusive from Digestive Disease Week 2022, Paul Feuerstadt, MD, FACG, AGAF, discussed studies assessing the investigational biotherapeutic, RBX2660, for the treatment of Clostridioides difficile.

SAN DIEGO — RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.

Phathom Pharmaceuticals Inc. has announced FDA approval for its Voquezna Triple and Dual Paks for the treatment of Helicobacter pylori infection in adults.